Becton Dickinson and Co BDX · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500
215.25
+1.59%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Becton Dickinson and Co
From its filings with the US Securities and Exchange Commission
Becton Dickinson and Co is based in Franklin Lakes, New Jersey and is incorporated in New Jersey. Its shares trade on NYSE under the ticker BDX. It is a member of the S&P 500. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 30 September 2025, it reported revenue of $21.84bn and net income of $1.68bn. At that date it held total assets of $55.33bn and shareholders' equity of $25.39bn.
BD is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. We provide customer solutions that are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology care; enhancing the diagnosis of infectious diseases and cancers; and advancing cellular research and applications.
As of September 30, 2025, BD’s operations consisted of three worldwide business segments: BD Medical, BD Life Sciences and BD Interventional. As further discussed in Note 8 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data, effective October 1, 2025, BD reorganized its organizational units into five distinct, separately-managed segments, based on the nature of BD’s product and service offerings. BD’s new organizational structure is based upon the following five segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences, which remains a critical part of BD until the separation and combination of our Biosciences and Diagnostic Solutions business with Waters Corporation (“Waters”), as further discussed below, is completed.
Quoted from its 10-K, filed 25 Nov 2025. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 25 Sept 1963
- Employees
- 72,000
- Website
- bd.com ↗
- Head office
- ONE BECTON DR, FRANKLIN LAKES, NJ, 07417-1880
- Incorporated in
- NJ
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Thomas PolenChairman of the Board, President, Chief Executive Officer, since 2014$17.3m
- Mr. Christopher DeloreficeChief Financial Officer, Executive Vice President$5.6m
- Ms. Shana NealChief People Officer, Executive Vice President$3.3m
- Mr. Antoine EzellExecutive Vice President, President, North America, Chief Marketing Officer
- Ms. Michelle QuinnExecutive Vice President, General Counsel
- Mr. Richard ByrdExecutive Vice President, President - Interventional Segment$3.3m
- Mr. Michael FeldExecutive Vice President, President - Life Sciences
- Mr. Michael GarrisonExecutive Vice President, President - Medical Segment$3.6m
- Mr. Roland GoetteExecutive Vice President, President - EMEA
- Mr. Pavan MocherlaExecutive Vice President, President - Greater Asia
- Mr. David ShanExecutive Vice President, Chief Integrated Supply Chain Officer
- Mr. Bertram ScottLead Independent Director$374,470
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 80
- Environment
- 75
- Social
- 93
- Governance
- 72
- Direct emissions (scope 1)
- 162,475 t
- Energy emissions (scope 2)
- 386,599 t
- Value chain emissions (scope 3)
- 6,633,180 t
- Women in the workforce
- 49%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Market leader: Becton Dickinson (BD) is a well-established and recognized company with a significant market share in the medical technology industry.
- Diverse product portfolio: BD offers a wide range of medical devices, diagnostics, and healthcare solutions, catering to various healthcare needs.
- Strong research and development (R&D): The company invests heavily in R&D, leading to innovative product offerings and technological advancements.
Weaknesses
- Product recalls: Like any other company in the industry, BD has faced product recall issues in the past, which can dent its reputation and consumer trust.
- High dependence on key customers: BD relies on a few major customers for a significant portion of its revenue, exposing it to potential revenue fluctuations.
- Increased competition: The medical technology space is highly competitive, with numerous competitors striving to gain market share.
Opportunities
- Growing healthcare industry: The healthcare sector's continuous expansion offers opportunities for BD to introduce new products and expand its customer base.
- Increasing demand for personalized medicine: BD can capitalize on the rising demand for personalized medicine by developing tailored diagnostics and treatment solutions.
- Emerging markets: Expanding into emerging markets, especially in regions like Asia and Latin America, can provide BD with new avenues for growth.
Threats
- Stringent regulations: Compliance with stringent regulations and obtaining necessary approvals for new products can pose challenges and delays for BD.
- Pricing pressures: Intense competition and pricing pressures in the industry can impact BD's profit margins and overall financial performance.
- Technological advancements: Rapid advancements in medical technology can render existing products obsolete, requiring BD to stay ahead of the curve.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.